HYMENIALDISINE AND DERIVATIVE THEREOF, PROCESS FOR PRODUCING INTERMEDIATE FOR SYNTHESIZING THE SAME, AND SAID INTERMEDIATE
申请人:SUNTORY LIMITED
公开号:EP0711773A1
公开(公告)日:1996-05-15
Hymenialdisine represented by general formula (I) and a derivative thereof, and a process for producing the same, wherein X¹ represents halogen or hydrogen. These compounds have a protein kinase C inhibitory effect and are expected as a remedy for diseases wherein protein kinase C activation is thought to participate.
通式(I)代表的海明二嗪及其衍生物,以及生产该物质的工艺,其中 X¹ 代表卤素或氢。这些化合物具有蛋白激酶 C 抑制作用,有望作为治疗被认为参与蛋白激酶 C 激活的疾病的药物。
US5621099A
申请人:——
公开号:US5621099A
公开(公告)日:1997-04-15
Synthetic method of hymenialdisine and its derivatives and their
申请人:Suntory Limited
公开号:US05621099A1
公开(公告)日:1997-04-15
The present invention provides hymenialdisine or its derivatives having the formula (I): ##STR1## wherein X.sup.1 is a halogen atom or a hydrogen atom and a process for production of the same. Further, synthetic intermediates are included in the invention. Hymenialdisine and its derivatives have inhibitory effects against protein kinase C and can be expected to have applications as a drug for the treatment of conditions where it is believed the activation of protein kinase C is involved.
A study on the acidcatalyzedhalogendance (ACHD) on deactivated bromopyrroles is reported. A different behavior is observed when considering singly deactivatedpyrrole alkylcarboxamides, or doubly deactivated pyrroleketo-lactams (aldisines). Although less electron deficient pyrrole alkylcarboxamides suffer from ACHD, the double deactivation on keto-lactams disfavors pyrrole ring protonation thus